Skip to main content
OpenTrials

Clinical trial condition

HR+/HER2- Breast Cancer

Explore clinical trials studying HR+/HER2- Breast Cancer. Study availability and eligibility vary by location and protocol.

25 public trials 15 recruiting studies
Refine in advanced search Browse all conditions

HR+/HER2- Breast Cancer trial results

Recruiting

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

NCT07492641

Conditions
HR+/HER2- Breast Cancer
Locations
  • Alabama Oncology Princeton Birmingham, Alabama, United States
  • Alaska Oncology and Hematology, Llc Anchorage, Alaska, United States
  • Ironwood Cancer and Research Centers Chandler Ii Chandler, Arizona, United States
  • Helios Clinical Research the Oncology Institute Fountain Valley Fountain Valley, California, United States
View all 108 locations
View Trial Details
Recruiting

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

NCT06998407

Conditions
HR+, HER2-, Advanced Breast Cancer, HR+/HER2- Breast Cancer
Locations
  • Avenzo Therapeutics Recruiting Site Los Angeles, California, United States
  • Avenzo Therapeutics Recruiting Site Los Angeles, California, United States
  • Avenzo Therapeutics Recruiting Site New Haven, Connecticut, United States
  • Avenzo Therapeutics Recruiting Site Orlando, Florida, United States
View all 16 locations
View Trial Details
Recruiting

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

NCT07242352

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus Mönchengladbach, North Rhine-Westphalia, Germany
  • Universitaetsklinikum Mannheim GmbH Frauenklinik Mannheim, Baden-Wurttemberg, Germany
  • Universitaetsklinikum Tuebingen AöR Frauenklinik Tübingen, Baden-Wurttemberg, Germany
  • Klinikum Esslingen GmbH Klinik für Frauenheilkunde und Geburtshilfe Esslingen am Neckar, Baden-Wüttemberg, Germany
View all 33 locations
View Trial Details
Recruiting

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

NCT07106632

Conditions
Breast Diseases, Breast Neoplasms, Early Breast Cancer, +6 more
Locations
  • Institut Jules Bordet Brussels, Belgium
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
  • Grand Hôpital de Charleroi Charleroi, Belgium
  • CHU Helora Hôpital de La Louvière - Site Jolimont Haine-Saint-Paul, Belgium
View all 105 locations
View Trial Details
Recruiting

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

NCT07702708

Conditions
Breast Diseases, Breast Neoplasms, HR+/HER2- Breast Cancer, +4 more
Locations
  • Fujian Cancer Hospital Fuzhou, Fujian, China
  • Fujian Provincial Hospital Fuzhou, Fujian, China
  • The Second Affiliated Hospital of Fujian Medical University Quanzhou, Fujian, China
  • Ningde First Hospital Ningde, China
View Trial Details
Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

NCT05867251

Conditions
Adnexal Diseases, Advanced Solid Tumor, Breast Diseases, +35 more
Locations
  • Yale Cancer Center New Haven, Connecticut, United States
  • Florida Cancer Specialists Sarasota, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Perlmutter Cancer Center at NYU Langone Hospital - Long Island Mineola, New York, United States
View all 13 locations
View Trial Details
Recruiting

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer (NEOTORCH-BREAST01)

NCT06611813

Conditions
Breast Diseases, Breast Neoplasms, HR+/HER2- Breast Cancer, +4 more
Locations
  • The First Affiliated Hospital of Zhejiang University Hangzhou, China
  • Zhejiang Cancer Hospital Hangzhou, China
  • Harbin Medical University Cancer Hospital Harbin, China
  • The First Affiliated Hospital of Anhui Medical University Hefei, China
View Trial Details

Related conditions